SiBone (NASDAQ:SIBN) Shares Climb 8.7% After Better-Than-Expected Earnings

SiBone (NASDAQ:SIBN)’s stock price rose 8.7% during mid-day trading on Tuesday after the company announced better than expected quarterly earnings. The company traded as high as $22.26 and last traded at $21.9880. 136,756 shares traded hands during mid-day trading, a decline of 78% from the average daily volume of 614,324 shares. The stock had previously closed at $20.22.

The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.05. SiBone had a negative net margin of 6.85% and a negative return on equity of 8.23%. The company had revenue of $55.70 million for the quarter, compared to analysts’ expectations of $55.31 million.

Key SiBone News

Here are the key news stories impacting SiBone this week:

• Positive Sentiment: Third-quarter results exceeded estimates. SiBone reported a loss of $0.08 per share, narrower than the $0.13 analyst consensus, while revenue increased 14.5% year over year to $55.7 million, slightly above expectations. The improved earnings performance may support the stock. Si-Bone Reports Q3 Loss, Tops Revenue Estimates
• Positive Sentiment: Growth and cash generation improved. U.S. procedure volume grew approximately 20%, the active U.S. physician base rose 16% to 1,770, adjusted EBITDA increased 32.4% to $3.0 million, and operating cash flow reached $5.9 million. SiBone ended the quarter with $146.3 million in cash. SiBone Third-Quarter Results
• Positive Sentiment: Product and reimbursement catalysts remain in place. FDA clearance for the iFuse Granite Onyx breakthrough device and new reimbursement rules that could increase hospital payments by up to approximately $50,000 for qualifying procedures may accelerate adoption.
• Neutral Sentiment: Full-year revenue guidance is essentially unchanged. SiBone forecast fiscal 2026 revenue of $231 million to $233 million, compared with the $232.2 million consensus estimate. The guidance is reassuring but does not represent a material forecast increase. The company remains unprofitable, posting a $3.6 million quarterly net loss.
• Negative Sentiment: Insiders sold shares. SVP Michael Pisetsky sold 29,665 shares for about $655,893, reducing his position by 15.28%, while Anshul Maheshwari sold 3,738 shares for $84,105. Both retained sizable holdings, but the transactions could create modest sentiment pressure. SiBone Insider Sales

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on SIBN. TD Cowen upped their target price on shares of SiBone from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Tuesday, August 4th. Weiss Ratings raised shares of SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 20th. Needham & Company LLC decreased their price objective on shares of SiBone from $27.00 to $26.00 and set a “buy” rating for the company in a report on Tuesday. Truist Financial upped their price objective on SiBone from $23.00 to $25.00 and gave the company a “buy” rating in a research report on Wednesday, October 14th. Finally, Citigroup reiterated a “market outperform” rating on shares of SiBone in a research note on Tuesday. Seven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $24.33.

Insiders Place Their Bets

In other SiBone news, SVP Michael Pisetsky sold 29,665 shares of the business’s stock in a transaction dated Thursday, October 29th. The stock was sold at an average price of $22.11, for a total value of $655,893.15. Following the completion of the transaction, the senior vice president owned 164,444 shares of the company’s stock, valued at approximately $3,635,856.84. The trade was a 15.28% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Laura Francis sold 38,006 shares of the company’s stock in a transaction dated Monday, October 12th. The shares were sold at an average price of $20.05, for a total transaction of $762,020.30. Following the transaction, the chief executive officer owned 379,256 shares in the company, valued at $7,604,082.80. This represents a 9.11% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 238,371 shares of company stock valued at $4,738,916 over the last quarter. Corporate insiders own 4.00% of the company’s stock.

Institutional Investors Weigh In On SiBone

Large investors have recently added to or reduced their stakes in the stock. Versant Capital Management Inc raised its stake in SiBone by 102.9% during the 2nd quarter. Versant Capital Management Inc now owns 1,749 shares of the company’s stock valued at $29,000 after buying an additional 887 shares during the last quarter. State of Wyoming boosted its stake in shares of SiBone by 70.8% in the 1st quarter. State of Wyoming now owns 10,832 shares of the company’s stock worth $137,000 after buying an additional 4,490 shares during the last quarter. Inceptionr LLC purchased a new position in shares of SiBone in the 1st quarter worth $156,000. ADAR1 Capital Management LLC purchased a new position in shares of SiBone in the 1st quarter worth $159,000. Finally, Elevation Point Wealth Partners LLC bought a new stake in shares of SiBone in the first quarter worth $204,000. Institutional investors own 98.11% of the company’s stock.

SiBone Stock Up 9.9%

The company has a market cap of $985.46 million, a P/E ratio of -65.17 and a beta of 0.66. The company has a quick ratio of 7.55, a current ratio of 9.15 and a debt-to-equity ratio of 0.20. The company has a fifty day moving average of $19.42 and a 200 day moving average of $16.45.

About SiBone

SI-BONE, Inc (NASDAQ: SIBN) is a medical device company focused on diagnosing and treating disorders of the sacroiliac joint, which connects the spine to the pelvis. The company develops minimally invasive surgical solutions intended to stabilize the sacroiliac joint and address sacroiliac joint dysfunction and related conditions.

Its product portfolio is centered on the iFuse Implant System, a family of triangular implants designed to be placed across the sacroiliac joint. SI-BONE also offers products such as iFuse-TORQ, a threaded implant system, and iFuse Bedrock Granite, which is designed for sacroiliac joint fusion and pelvic fixation as part of certain spinal procedures.